Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not yet recruitingRare disease

Study of Radspherin® for Patients with Peritoneal Cancer from Colorectal Cancer After Surgery and Chemotherapy

Verified siteInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a condition known as peritoneal carcinomatosis, which occurs when cancer cells spread to the lining of the abdominal cavity. This condition is often associated with colorectal cancer, a type of cancer that begins in the colon or rectum. The trial will investigate the effects of a treatment called Radspherin, which is a suspension for injection containing radium-224 adsorbed in calcium carbonate microparticles. This treatment is designed to be administered directly into the abdominal cavity, a method known as intraperitoneal use.

The purpose of the study is to compare the time patients live without their disease getting worse after receiving Radspherin compared to those who do not receive this treatment. Participants in the study will have undergone a procedure called cytoreductive surgery, which aims to remove as much of the tumor as possible, followed by hyperthermic intraperitoneal chemotherapy (HIPEC), a treatment that involves heating chemotherapy drugs and delivering them directly into the abdominal cavity. The study will follow participants over a period of time to monitor their health and any changes in their condition.

Throughout the study, participants will undergo regular assessments, including imaging tests like CT or MRI, to evaluate the progression of their disease. The study will also track overall survival, changes in specific blood markers, and any side effects experienced by participants. The goal is to gather information on the safety and effectiveness of Radspherin in treating peritoneal carcinomatosis from colorectal cancer.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, the patient will be informed about the trial's purpose and procedures. Written informed consent is required to participate.

    For females of childbearing potential, a negative pregnancy test must be documented before enrollment. Both male and female participants must agree to use effective contraception during the treatment period and for a specified time afterward.

  2. Step 2

    Initial assessment

    The patient will undergo an initial assessment to confirm eligibility. This includes verifying a diagnosis of colorectal carcinoma with peritoneal metastases and ensuring adequate organ function.

    The patient's performance status will be evaluated using the Eastern Cooperative Oncology Group (ECOG) scale, and laboratory tests will be conducted to assess renal, hepatic, and bone marrow function.

  3. Step 3

    Treatment administration

    The treatment involves the administration of Radspherin, a suspension for injection containing radium-224 adsorbed in calcium carbonate microparticles.

    The medication is administered intraperitoneally, meaning it is injected into the abdominal cavity. The exact dosage and frequency will be determined by the study protocol.

  4. Step 4

    Monitoring and follow-up

    The patient will be monitored for progression-free survival (PFS), which is the time from randomization until disease progression or death.

    Regular assessments using imaging techniques like CT or MRI will be conducted to evaluate the response to treatment according to established criteria.

    Secondary outcomes such as overall survival (OS), changes in biomarkers, and quality of life will also be monitored.

  5. Step 5

    Completion and evaluation

    The study is expected to continue until March 2031. Upon completion, the patient's data will be analyzed to assess the efficacy and safety of the treatment.

    The incidence and severity of any adverse events will be recorded and evaluated throughout the study period.

Who can join the trial?

14 criteria

  • Must be able and willing to provide written consent and follow the study rules.
  • Females who can have children must have a negative pregnancy test before joining.
  • Females who can have children must agree to use a highly effective birth control method during the study and for at least 9 months if they receive the treatment. This includes options like:
    • Female sterilization (surgical removal of ovaries or uterus, or tying of fallopian tubes).
    • Use of hormonal birth control methods like pills, injections, implants, or devices placed inside the uterus.
    • Non-sterile males with female partners who can have children must agree to use condoms during the study and for at least 6 months if they receive the treatment. The female partner should also use a highly effective birth control method.
    • Non-sterile males must agree not to donate sperm during the study and for up to 6 months after receiving the treatment.
    • Must be 18 years or older.
    • Must have a confirmed diagnosis of colorectal cancer. If the cancer has returned and spread to the peritoneal cavity, a biopsy during surgery is acceptable to confirm this.
    • Must have peritoneal metastases that can be surgically removed with the goal of leaving no visible tumor.
    • Any side effects from previous cancer treatments must have improved to at least a mild level, except for hair loss.
    • Must have an Eastern Cooperative Oncology Group (ECOG) Performance Status Score of 0 to 1, which means being fully active or having some symptoms but being able to carry out light work.
    • Must have adequate kidney function, with a creatinine clearance of at least 40 ml/min.
    • Must have adequate liver function, with serum bilirubin less than 1.5 times the normal limit, and liver enzymes (AST and ALT) no more than 3 times the normal limit.
    • Must have adequate bone marrow function, with a certain level of white blood cells, platelets, and hemoglobin.

Who cannot join the trial?

1 criterion

  • Patients with **carcinomatosis of the peritoneal cavity** cannot participate. This means cancer has spread to the lining of the abdomen.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Radspherin® is a type of therapy that uses a radioactive substance to target cancer cells. In this trial, it is used to treat patients with cancer that has spread to the lining of the abdomen from colorectal cancer. The treatment is given directly into the abdominal cavity after surgery to remove as much of the cancer as possible and after a special type of chemotherapy that is heated and also given directly into the abdomen. The goal of Radspherin® is to help stop the cancer from growing and spreading further.

What is already known about the treatment

Radspherin – This medication is administered intraperitoneally, meaning it is delivered directly into the abdominal cavity. It is currently being studied in clinical trials for its effectiveness and safety in treating peritoneal carcinomatosis, a condition where cancer spreads to the lining of the abdominal cavity, particularly from colorectal cancer. Radspherin works by using a radioactive substance that emits alpha particles, which can destroy cancer cells at a molecular level. It is classified as a radionuclide therapy, a type of treatment that uses radioactive substances to target and kill cancer cells.

Investigated diseases

Carcinomatosis of peritoneal cavity – This condition involves the spread of cancer cells to the lining of the abdominal cavity, known as the peritoneum. It often originates from primary tumors in organs such as the colon, stomach, or ovaries. As the disease progresses, cancer cells implant on the peritoneal surface, leading to the formation of multiple small tumors. This can cause the peritoneum to thicken and produce excess fluid, resulting in abdominal swelling and discomfort. Over time, the accumulation of cancerous cells can interfere with normal organ function within the abdominal cavity. The progression of the disease can vary depending on the primary cancer type and individual patient factors.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2023-508496-37-00Protocol codeRAD-18-004Estimated enrolment102 patientsSponsorOncoinvent Solutions AS

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).